Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis for recreational and medical purposes primarily in Canada, the United States, Germany, and the United Kingdom. More Details
High growth potential with adequate balance sheet.
Share Price & News
How has Canopy Growth's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: WEED is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: WEED's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: WEED exceeded the Canadian Pharmaceuticals industry which returned 18.9% over the past year.
Return vs Market: WEED exceeded the Canadian Market which returned 0.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Canopy Growth's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDoes Canopy Growth (TSE:WEED) Have A Healthy Balance Sheet?
2 months ago | Simply Wall StCanopy Growth Corporation's (TSE:WEED) Profit Outlook
4 months ago | Simply Wall StHere's What Canopy Growth Corporation's (TSE:WEED) Shareholder Ownership Structure Looks Like
Is Canopy Growth undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: WEED (CA$36.39) is trading below our estimate of fair value (CA$47.91)
Significantly Below Fair Value: WEED is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: WEED is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: WEED is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate WEED's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: WEED is overvalued based on its PB Ratio (2.8x) compared to the CA Pharmaceuticals industry average (1.7x).
How is Canopy Growth forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: WEED is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: WEED is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: WEED's is expected to become profitable in the next 3 years.
Revenue vs Market: WEED's revenue (34.4% per year) is forecast to grow faster than the Canadian market (6.2% per year).
High Growth Revenue: WEED's revenue (34.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: WEED is forecast to be unprofitable in 3 years.
How has Canopy Growth performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WEED is currently unprofitable.
Growing Profit Margin: WEED is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: WEED is unprofitable, and losses have increased over the past 5 years at a rate of 73.6% per year.
Accelerating Growth: Unable to compare WEED's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WEED is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-45%).
Return on Equity
High ROE: WEED has a negative Return on Equity (-32.23%), as it is currently unprofitable.
How is Canopy Growth's financial position?
Financial Position Analysis
Short Term Liabilities: WEED's short term assets (CA$2.3B) exceed its short term liabilities (CA$324.5M).
Long Term Liabilities: WEED's short term assets (CA$2.3B) exceed its long term liabilities (CA$1.1B).
Debt to Equity History and Analysis
Debt Level: WEED's debt to equity ratio (10.4%) is considered satisfactory.
Reducing Debt: WEED's debt to equity ratio has increased from 5.2% to 10.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: WEED has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if WEED has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Canopy Growth current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate WEED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate WEED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if WEED's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WEED's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of WEED's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Klein (56 yo)
Mr. David Eric Klein has been the Chief Executive Officer at Canopy Growth Corporation since January 14, 2020 and has been its Director since November 1, 2018. Mr. Klein served as Chairman of the Board at ...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD48.96M) is above average for companies of similar size in the Canadian market ($USD7.04M).
Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.
|CEO & Director||0.92yr||CA$34.54m||no data|
|President & Chief Product Officer||1.42yrs||CA$3.16m||0.040% |
|Executive VP & CFO||1.5yrs||CA$2.16m||0.040% |
|VP & Chief Accounting Officer||no data||CA$1.92m||0.0074% |
|Chief Legal Officer||no data||CA$719.29k||0.0089% |
|Strategic Advisor||1.5yrs||CA$2.16m||0.12% |
|Interim COO & VP of Operations Transformation||0.50yr||no data||no data|
|Senior VP of Quality Assurance & Chief Science Officer||2.25yrs||no data||0% |
|Chief Human Resources Officer||no data||no data||no data|
|Head of Agriculture - Hemp Division||no data||no data||no data|
|Chief Medical Officer||2.42yrs||no data||no data|
|Chief Advocacy Officer||1.83yrs||no data||no data|
Experienced Management: WEED's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
|CEO & Director||0.92yr||CA$34.54m||no data|
|Independent Director||0.75yr||CA$105.65k||0.00022% |
|Independent Director||2.08yrs||no data||no data|
|Independent Director||2.08yrs||CA$20.05k||0.00090% |
|Independent Chairman||0.92yr||CA$323.02k||0.0030% |
|Director||0.25yr||no data||0.00040% |
|Independent Director||0.75yr||CA$105.65k||0.0015% |
Experienced Board: WEED's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: WEED insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.8%.
Canopy Growth Corporation's company bio, employee growth, exchange listings and data sources
- Name: Canopy Growth Corporation
- Ticker: WEED
- Exchange: TSX
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$12.851b
- Shares outstanding: 372.28m
- Website: https://www.canopygrowth.com
Number of Employees
- Canopy Growth Corporation
- 1 Hershey Drive
- Smiths Falls
- K7A 0A8
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|WEED||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Mar 2014|
|CGC||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Mar 2014|
|11L1||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2014|
|0UO9||LSE (London Stock Exchange)||Yes||Common Shares||GB||CAD||Mar 2014|
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis for recreational and medical purposes primarily in Canada, the United States, German...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/02 23:11|
|End of Day Share Price||2020/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.